30 closest matches · ranked by relevance
Neuroendocrine Tumors · Neuroendocrine Neoplasm of Lung
Primary: Clinical Benefit Rate (CBR) — 0; 0; 0; 1 Participants
Pancreatic Endocrine Neoplasms
Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants
Carcinoid Tumor · Metastatic Carcinoid Tumor · Neuroendocrine Neoplasm
Primary: PFS — 11 months
Gastrinoma · Glucagonoma · Insulinoma
Primary: PFS
Gastrinoma · Glucagonoma · Insulinoma
Primary: Confirmed Response Rate — 10; 14 percentage of participants
High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
Primary: Overall Response Rate (ORR) — 7; 5 percentage of participants
Neuroendocrine Tumors · Neuroendocrine Neoplasm · Gastroenteropancreatic Neuroendocrine Tumor
Primary: Overall Survival Rate at 12 Months — 54.1 % of participants
Carcinoid Tumor · Carcinoid Tumor of GI System · Neuroendocrine Tumors
Primary: Objective Response Rate (ORR) — 0 percentage of participants
Neuroendocrine Carcinoma
Primary: Number of Patients That Experienced a Change in Care Plans After 68GA-DOTATATE PET Scan — 19; 9; 50 participants
Recurrent Neuroendocrine Tumor · Metastatic Neuroendocrine Tumor
Primary: Tumor Response According to RECIST Criteria — 0; 0; 0; 5 Participants
Gastroenteropancreatic Neuroendocrine Tumor
Primary: Prevalence of Malnutrition in GEP NET — 247; 152 Participants
Well-differentiated Non-functional NET of Thoracic Origin · Well-differentiated Non-functional NET of Gastrointestinal Origin · Well-differentiated Non-functional NET of Pancreatic Origin
Primary: Overall Response Rate (ORR) by RECIST 1.1 and as Per Blinded Independent Central Review (BIRC). — 7.4; 4.8 Percentage of participants
Neuroendocrine Tumors
Primary: Number of Participants With Partial Response (PR) — 9 participants
Neuroendocrine Tumors · Von Hippel-Lindau Syndrome · Hippel-Lindau Disease
Primary: Number of Lesions Detected Using the 68Gallium-DOTATATE Positron Emission Tomography (PET/Computed Tomography (CT)) Scan — 847 Number of lesions
Advanced/Metastatic Neuroendocrine Tumors
Primary: Clinical Benefit Rate — 11 Participants
Neuroendocrine Tumors
Primary: Best Response Rate by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 Upon Central Radiologic Assessment — 0; 0; 23; 9 Participants
Neuroendocrine Tumors
Primary: Number of Participants With Improved, Stable, or Worsened Change In Chromogranin A (CgA) Biomarker Levels From Baseline — 1; 11; 6 Participants
Neuroendocrine Tumors
Primary: 12-month Progression Free Survival (PFS) — 64.7 percentage of participants w/ 12 mo PFS
Neuroendocrine Tumors
Primary: Sensitivity to Correctly Diagnose NET — 75; 75; 100; 75 percent of NET correctly diagnosed
Metastatic Gastrointestinal Carcinoid Tumor · Pulmonary Carcinoid Tumor · Recurrent Gastrointestinal Carcinoid Tumor
Primary: Objective Tumor Response Rate (Defined as Partial or Complete Response as Defined by the RECIST Criteria) — 2 participants
Neuroendocrine Cancer
Primary: Overall Response Rate (ORR) — 3.226 percentage of participants
Gastrin-Producing Neuroendocrine Tumor · Lung Carcinoid Tumor · Metastatic Digestive System Neuroendocrine Tumor G1
Primary: Objective Response Rate (Complete and Partial Response) for Each Cohort Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) — 0; 6; 14; 21 participants
Neuroendocrine Tumors · Metastatic Neuroendocrine Tumors
Primary: Objective Response Rate (ORR) — 13; 12 participants
Large-Cell Neuroendocrine Carcinoma
Primary: Sequencing Rate (Feasibility)
Neuroendocrine Tumors · Carcinoid Tumors · Neuroblastoma
Primary: Number of Participants With a Change in Treatment Management Based on Findings of the Gallium Ga 68-edotreotide PET/CT Scan — 54; 6; 54 Participants
Neuroendocrine Tumor · Carcinoid Tumor · Pancreatic Neuroendocrine Tumor
Primary: Objective Response Rate — 0.0 percentage of patients
Neuroendocrine Tumors
Primary: Time to Tumor Progression Documented by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) — 14.3; 6.0 Months
Gastrointestinal Carcinoid Tumor · Islet Cell Tumor · Neoplastic Syndrome
Primary: Four-month Progression-free Survival Rate — 78.5 percentage of participants — p=<0.001
Neuroendocrine Tumors
Primary: Objective Response Rate (ORR) — 1 Participants
Neuroendocrine Tumors · Carcinoid Tumors
Primary: Progression-free Survival (PFS) at One Year — 11 months